Research programme: ubiquitin-proteasome inhibitors - Takeda Oncology

Drug Profile

Research programme: ubiquitin-proteasome inhibitors - Takeda Oncology

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium Pharmaceuticals; sanofi-aventis; Takeda Oncology
  • Class RNA
  • Mechanism of Action Immunomodulators; Proteasome inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Asthma; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 14 May 2008 Millennium Pharmaceuticals has been acquired by Takeda
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top